B-Cell Lymphomas Coverage from Every Angle
Advertisement
Advertisement

Published Medical Literature

From the Haematological Malignancy Research Network: Expanded Database May Yield Insights in B-Cell Lymphomas
Clinical Characteristics of Diffuse Large B-Cell Lymphoma Manifesting in the Jaw
Does Microenvironment Impact the Pathogenesis of MALT Lymphomas?
Does the MYC/MYB/ZDHHC11 Network Impact the Growth of B-Cell Malignancies?
First-Line Ibrutinib Plus Rituximab in Elderly Patients With Mantle Cell Lymphoma
Loncastuximab Tesirine-lpyl for DLBCL: Quality of Life for Older Versus Younger Patients
Prognostic Analyses of Genetic Subtypes Within Diffuse Large B-Cell Lymphoma
Immunogenicity Profile of Tisagenlecleucel in Diffuse Large B-Cell Lymphoma
Biomarkers and Pathways Associated With B-Cell Lymphoma
Exploring the Function of Transcription Factor 3 and Histone Deacetylase 3 in Burkitt Lymphoma
Impact of FLI1 Expression Levels in Germinal Center–Derived DLBCL
Heterologous SARS–CoV-2 Vaccination for Patients With B-Cell Lymphoma
Zanubrutinib Monotherapy for Mantle Cell Lymphoma: Pooled Analysis of Two Trials
Phase II Trial of Combination Therapy for Children and Adolescents With Primary Mediastinal B-Cell Lymphoma
Polatuzumab Vedotin-piiq–Based Salvage Chemotherapy for DLBCL
The Role of Protein Kinase CK1α in Mantle Cell Lymphoma
Zanubrutinib Versus Standard BTK Inhibitors in B-Cell Malignancy: Pooled Safety Analysis
Early-Phase Study of Combination BTK and PI3K Inhibition as B-Cell Lymphoma Therapy
Polatuzumab Vedotin-piiq–Based Therapy for Previously Untreated DLBCL: POLARIX Trial
Older Patients With Mantle Cell Lymphoma: Phase II Trial Focuses on Ibrutinib Plus Rituximab
Tisagenlecleucel Versus Standard of Care in Second-Line Therapy for Aggressive B-Cell Lymphomas
Evaluation of B-Cell Gene Signatures Using Immunomagnetic Cell Separation
Predictability of MCL1 and BCL2 Expression as Sensitivity Biomarkers in B-Cell Lymphomas
Axicabtagene Ciloleucel Versus Standard-of-Care Therapy for Resistant B-Cell Lymphoma
Prognostic Factors of Rheumatic Disease–Associated DLBCL


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.